CTMX Stock Analysis: Buy, Sell, or Hold?
CTMX - CytomX Therapeutics, Inc.
$4.12
-0.17 (-3.96%)
▼
5d:
-13.45%
30d:
-8.85%
90d:
-30.52%
HOLD
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 11, 2026
11d
Smart Money Accumulation
CTMX is down 8.7% this week, but smart money is accumulating calls. Top strike: $6 2026-06-18 with 751 OI. Call ratio: 95% View Scanner →
Strength: 8.8/10
Get Alerted When CTMX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTMX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CTMX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CTMX is currently trading at $4.12, which is considered oversold relative to its 30-day fair value range of $4.27 to $4.68.
Technical Outlook: Technically, CTMX is in a downtrend. The price is currently testing key support at $4.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: CTMX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.67 (+231.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTMX is in a downtrend. The price is currently testing key support at $4.10. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: CTMX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.67 (+231.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.27 -
$4.68
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 231.7% below Wall St target ($13.67)
- CAUTION: 5-day price weakness (-13.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$4.27 -
$4.68
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.10
Resistance Level
$5.08
Current Trend
Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.71
Wall Street Target
$13.67
(+231.7%)
Revenue Growth (YoY)
-98.3%
Earnings Growth (YoY)
60.6%
Profit Margin
-22.8%
Share & Embed Analysis
Last updated: April 29, 2026 4:25 AM ET
Data refreshes hourly during market hours. Next update: 5:25 AM
Data refreshes hourly during market hours. Next update: 5:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTMX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Christopher Ogden
SELL
19323 shares
2026-03-17
Marcia Belvin
SELL
31492 shares
2026-03-17
Sean A Mccarthy
SELL
118969 shares
2026-03-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 65 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$226 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 55 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 51 HOLD |
